TSX:IMV (Imv)
About IMV
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.
Imv (TSX: IMV) Latest News

Stocks for Beginners
3 Under-$5 TSX Stocks That Could Double in a Year

Investing
Value Investing: 1 Pharma Stock to Buy in June 2021

Investing
44% of Canadians Will Get Cancer: This 1 Stock Will Skyrocket!

Dividend Stocks
Cure Recession Blues With These Red-Hot Healthcare Stocks

Dividend Stocks
3 Top Canadian Healthcare Stocks for Growth Investors

Investing
2 Biotech Stocks at 52-Week Lows: Should You Buy Today?
